The pharmacogenomics of osteosarcoma.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 3. J Immunother Cancer. 2021 Feb;9(2):e001580. doi: 10.1136/jitc-2020-001580. Immunotherapy for sarcomas: new frontiers and unveiled opportunities. Birdi HK(#)(1)(2)(3), Jirovec A(#)(1)(2)(3), Cortés-Kaplan S(#)(1)(2)(3), Werier J(4)(5), Nessim C(1)(5), Diallo JS(#)(1)(2)(3), Ardolino M(#)(6)(2)(3). Author information: (1)Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. (2)Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada. (3)CI3, University of Ottawa, Ottawa, Ontario, Canada. (4)Department of Surgery, University of Ottawa, Ottawa, Ontario, Canada. (5)Clinical Epidemiology Unit, Ottawa Hospital Reseach Institute, Ottawa, Ontario, Canada. (6)Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada mardolino@ohri.ca. (#)Contributed equally Erratum in J Immunother Cancer. 2022 Apr;10(4):e001580corr1. doi: 10.1136/jitc-2020-001580corr1. Sarcomas are a rare malignancy of mesenchymal tissues, comprizing a plethora of unique subtypes, with more than 60 types. The sheer heterogeneity of disease phenotype makes this a particularly difficult cancer to treat. Radiotherapy, chemotherapy and surgery have been employed for over three decades and, although effective in early disease (stages I-II), in later stages, where metastatic tumors are present, these treatments are less effective. Given the spectacular results obtained by cancer immunotherapy in a variety of solid cancers and leukemias, there is now a great interest in appliying this new realm of therapy for sarcomas. The widespread use of immunotherapy for sarcoma relies on immuno-profiling of subtypes, immunomonitoring for prognosis, preclinical studies and insight into the safety profile of these novel therapies. Herein, we discuss preclinical and clinical data highlighting how immunotherapy is being used in soft tissue sarcoma and bone sarcomas. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. DOI: 10.1136/jitc-2020-001580 PMCID: PMC7852926